Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.
Follow ALNY
Alnylam Pharmaceuticals, Inc. (ALNY) P/E ratio
As of 16 October 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a P/E ratio of 39.5×. Over the past ten years it has ranged from 0.0× (September 2025) to 806× (October 2025); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 163× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 51.3× | (35.99%) |
| Mar 2026 | 80.1× | (50.87%) |
| Dec 2025 | 163× | (78.20%) |
| Sep 2025 | 748× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| BNTX BioNTech SE Sponsored ADR compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| INCY Incyte Corporation compare | 13.9× |
| GMAB Genmab A/S Sponsored ADR compare | 29.1× |
| ALNY Alnylam Pharmaceuticals, Inc. | 39.5× |
| RPRX Royalty Pharma PLC compare | 42.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 62.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)